Glenmark gets tentative nod from USFDA for azelaic acid gel
NEW DELHI: Glenmark Pharmaceuticals today announced receipt of tentative approval from USFDA for its generic version of azelaic acid topical gel used for treating skin inflammation.Glenmark will market this product upon receiving final approval, it said, adding that the patent for Finacea topical gel, 15 per cent, is scheduled to expire on November 18, 2018.The tentative nod granted to...
Login or Register to read the full article
NEW DELHI: Glenmark Pharmaceuticals today announced receipt of tentative approval from USFDA for its generic version of azelaic acid topical gel used for treating skin inflammation.
Glenmark will market this product upon receiving final approval, it said, adding that the patent for Finacea topical gel, 15 per cent, is scheduled to expire on November 18, 2018.
The tentative nod granted to Glenmark Pharmaceuticals Inc, USA, by the US Food and Drug Administration (USFDA) is for azelaic acid gel, 15 per cent, the generic version of Finacea topical gel, 15 per cent of Bayer Healthcare, the company said in a BSE filing.
Citing IMS Health sales data, the company said for the 12 months ending December 2015, the Finacea market achieved annual sales of approximately USD 128 million.
The company's current portfolio consists of 106 products authorised for distribution in the US and 62 Abbreviated New Drug Applications (ANDAs) pending approval with USFDA, it said.
The stock was trading at Rs 708 in the mid-day trade, up 0.54 per cent from the previous close.
Glenmark will market this product upon receiving final approval, it said, adding that the patent for Finacea topical gel, 15 per cent, is scheduled to expire on November 18, 2018.
The tentative nod granted to Glenmark Pharmaceuticals Inc, USA, by the US Food and Drug Administration (USFDA) is for azelaic acid gel, 15 per cent, the generic version of Finacea topical gel, 15 per cent of Bayer Healthcare, the company said in a BSE filing.
Citing IMS Health sales data, the company said for the 12 months ending December 2015, the Finacea market achieved annual sales of approximately USD 128 million.
The company's current portfolio consists of 106 products authorised for distribution in the US and 62 Abbreviated New Drug Applications (ANDAs) pending approval with USFDA, it said.
The stock was trading at Rs 708 in the mid-day trade, up 0.54 per cent from the previous close.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd